"Factor IXa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Activated form of factor IX. This activation can take place via the intrinsic pathway of blood coagulation by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.
| Descriptor ID |
D015949
|
| MeSH Number(s) |
D08.811.277.656.300.760.310 D08.811.277.656.959.350.310 D12.776.124.125.375.310 D23.119.375.310
|
| Concept/Terms |
Factor IXa- Factor IXa
- Coagulation Factor IXa
- Factor IXa, Coagulation
- Blood Coagulation Factor IX, Activated
- Factor IX, Activated
- Activated Factor IX
- Factor 9A
- Factor Nine A
|
Below are MeSH descriptors whose meaning is more general than "Factor IXa".
Below are MeSH descriptors whose meaning is more specific than "Factor IXa".
This graph shows the total number of publications written about "Factor IXa" by people in this website by year, and whether "Factor IXa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor IXa" by people in Profiles.
-
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation. 2010 Aug 10; 122(6):614-22.
-
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 Jun 03; 117(22):2865-74.
-
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Dec 05; 114(23):2490-7.